Skip to main content
Eligibility
for people ages 65–85
Healthy Volunteers
healthy people welcome
Location
at San Francisco, California and other locations
Dates
study started
estimated completion:
Principal Investigator

Description

Summary

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).

Official Title

Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)

Details

The A4 study is a clinical trial for older individuals who have evidence of amyloid plaque build-up in their brains who may be at risk for memory loss and cognitive decline due to Alzheimer's disease. The A4 study will test an anti-amyloid investigational drug in older individuals who do not yet show symptoms of Alzheimer's disease cognitive impairment or dementia with the aim of slowing memory and cognitive decline. The A4 study will also test whether anti-amyloid treatment can delay the progression of AD related brain injury on imaging and other biomarkers.

Keywords

Cognition Disorders Cognition Prevention

Eligibility

You can join if…

Open to people ages 65–85

  • Has a Mini-Mental State Examination (MMSE) score at screening of 25 to 30
  • Has a global Clinical Dementia Rating (CDR) scale score at screening of 0
  • Has a Logical Memory II score at screening of 6 to 18
  • Has a florbetapir positron emission tomography (PET) scan that shows evidence of brain amyloid pathology at screening
  • Has a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication)

You CAN'T join if...

  • Is receiving a prescription acetylcholinesterase inhibitor (AChEI) and/or memantine at screening or baseline
  • Lacks good venous access, such that intravenous drug delivery or multiple blood draws would be precluded
  • Has current serious or unstable illness including cardiovascular, hepatic, renal,gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic,or hematologic disease or other conditions that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study
  • Has had a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in protracted loss of consciousness
  • Has had a history within the last 5 years of a primary or recurrent malignant disease with the exception of resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ prostate cancer with normal prostate-specific antigen posttreatment
  • Has a known history of human immunodeficiency virus (HIV), clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis)
  • Is clinically judged by the investigator to be at serious risk for suicide
  • Has a history within the past 2 years of major depression or bipolar disorder as defined by the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM)
  • Has a history within the past 5 years of chronic alcohol or drug abuse/dependence as defined by the most current version of the DSM

Locations

  • University of California, Davis - Health Systems accepting new patients
    Walnut Creek, California, 94598, United States
  • Stanford University accepting new patients
    Palo Alto, California, 94304, United States
  • Sutter Medical Group accepting new patients
    Sacramento, California, 95816, United States
  • University of Southern California School of Medicine accepting new patients
    Los Angeles, California, 90033, United States
  • University of California - Los Angeles accepting new patients
    Los Angeles, California, 90095, United States
  • Univ of California Irvine College of Medicine accepting new patients
    Orange, California, 92868, United States
  • Syrentis Clinical Research accepting new patients
    Santa Ana, California, 92705, United States
  • Institute for Memory Impairment & Neurological Disorders accepting new patients
    Irvine, California, 92697, United States
  • Cleveland Clinic of Las Vegas accepting new patients
    Las Vegas, Nevada, 89106, United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
Click here for more information about this study: A Study of Solanezumab in Older Participants Who May be at Risk for Memory Loss (A4)
ID
NCT02008357
Phase
Phase 3
Lead Scientist
Adam Boxer
Study Type
Interventional
Last Updated
March 1, 2017
I'm interested in this study!